Jump to content

Thyroid imaging

From Surgopaedia

Ultrasound

[edit | edit source]
  • Advantages
    • Most accurate visualisation of thyroid nodular disease
    • Information about overall thyroid size and vascularity
    • Presence of cervical lymphadenopathy (good for lateral neck, not as good for central neck compartment)
    • Can be used to localise parathyroid disease
  • Normally homogenously echogenic, with a uniform echotexture

Nuclear scintigraphy

[edit | edit source]
  • Either technetium-99m pertechnetate or a radiolabelled iodine nuclide
    • The technetium-99 - pertechnetate complex is taken up by the thyroid instead of iodine, and patients can then be imaged to show the distribution of active thyroid tissue
  • Normally symmetrical uptake bilaterally
  • Divides nodules into 'hot' or 'cold'
    • Cold nodules have a 15% risk of malignancy, whereas hot nodules are generally benign
  • Indications
    • In hyperthyroidism to differentiate between Graves and solitary toxic adenoma/TMNG
    • Differentiated thyroid cancer - check for recurrent or metastatic disease

Iodine nuclide scan

[edit | edit source]
  • I-123 is the diagnostic scan to assess malignancies for uptake on I-131
  • I-131 is the therapeutic vehicle for treating malignancies
  • Both done as whole-body scan
  • Anatomical information - substernal goitre and advanced thyroid cancer
  • IV contrast in thyroid disease
    • IV contrast expands the iodine blood pool, which is subsequently taken up by the thyroid
    • Technetium studies won't be useful until this is cleared, because the thyroid won't take up technetium if it is already engorged with iodine
    • Iodine generally cleared 4-8 weeks after contrast administration
    • IV contrast can also worsen/precipitate hyperthyroidism in Graves or toxic nodules or hyperthyroid phase of Hashimoto's, but only really if it's poorly-controlled - it's ok if they have normal TFTs, and generally also ok if they're on treatment. This hyperthyroid storm would occur some weeks after administration.

PET-FDG

[edit | edit source]
  • Similar uptake to surrounding muscle in the normal thyroid
  • Not routinely used, but useful in some cancers

Sestamibi-SPECT

[edit | edit source]
  • Uses Tc-99m-sestamibi
  • Differential uptake and retention of radiotracer in mitochondria-rich cells of metabolically active tissues (sestamibi is a chemical that gets picked up by cells with lots of mitochondria, like heart and parathyroid)
  • Hyperfunctioning parathyroid glands preferentially take up and retain the tracer - best demonstrated on the 2 hour scan
  • Sensitivity 79% for adenoma, 44% for multi-gland disease
  • Addition of ultrasound improves sensitivity further

4D-CT

[edit | edit source]
  • Four dimensions - non-con, early arterial (45 seconds), delayed (75 seconds), and an assessment of the change in perfusion over time
  • Time is the fourth dimension here - the number of phases is not necessarily four
  • Parathyroid adenoma has lower attenuation compared to thyroid on non-con (45 HU compared to 90), rapid enhancement with maximum attenuation values of about 130HU in arterial, and then rapid washout of contrast material in the delayed phase
  • Conversely, normal thyroid and parathyroid tissue progressively enhances through the phases
  • Sensitivity 81-89% for adenoma, 55% for multi-gland disease
  • Particularly useful for small adenomas and abnormal glands or in re-operative cases